{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:11:07Z","timestamp":1787670667132,"version":"build-2736575974"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/nrneph.2013.225","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T09:40:05Z","timestamp":1383644405000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Treatment of ANCA-associated vasculitis"],"prefix":"10.1038","volume":"10","author":[{"given":"Ulf","family":"Sch\u00f6nermarck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"key":"BFnrneph2013225_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C.  et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 65, 1\u201311 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.lpm.2013.01.003","volume":"42","author":"CJ Jennette","year":"2013","unstructured":"Jennette, C. J. & Falk, R. J. L1. Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. Presse Med. 42, 493\u2013498 (2013).","journal-title":"Presse Med."},{"key":"BFnrneph2013225_CR3","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/ndt\/gfs062","volume":"27","author":"RJ Pepper","year":"2012","unstructured":"Pepper, R. J. & Salama, A. D. Classifying and predicting outcomes in ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 27, 2135\u20132137 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013225_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.lpm.2013.01.027","volume":"42","author":"D Jayne","year":"2013","unstructured":"Jayne, D. L27. Antibodies versus phenotypes: a clinician's view. Presse Med. 42, 579\u2013582 (2013).","journal-title":"Presse Med."},{"key":"BFnrneph2013225_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons, P. A.  et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214\u2013223 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013225_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/art.1780351113","volume":"35","author":"GS Hoffman","year":"1992","unstructured":"Hoffman, G. S., Leavitt, R. Y., Kerr, G. S. & Fauci, A. S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 35, 1322\u20131329 (1992).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/art.20234","volume":"51","author":"MC Slot","year":"2004","unstructured":"Slot, M. C., Tervaert, J. W., Boomsma, M. M. & Stegeman, C. A. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 51, 269\u2013273 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little, M. A.  et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036\u20131043 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann, O.  et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488\u2013494 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrneph.2012.107","volume":"8","author":"N Wall","year":"2012","unstructured":"Wall, N. & Harper, L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat. Rev. Nephrol. 8, 523\u2013532 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2013225_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/art.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"Holle, J. U.  et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 63, 257\u2013266 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ndt\/gfs428","volume":"28","author":"M Hilhorst","year":"2013","unstructured":"Hilhorst, M.  et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol. Dial. Transplant. 28, 373\u2013379 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013225_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","volume":"2","author":"EW Walton","year":"1958","unstructured":"Walton, E. W. Giant cell granuloma of the respiratory tract (Wegener's Granulomatosis). BMJ 2, 265\u2013270 (1958).","journal-title":"BMJ"},{"key":"BFnrneph2013225_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman, G. S.  et al. Wegener's granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488\u2013498 (1992).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2013225_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper, L.  et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71, 955\u2013960 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K de Groot","year":"2009","unstructured":"de Groot, K.  et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670\u2013680 (2009).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2013225_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ndt\/gfh563","volume":"20","author":"I Neumann","year":"2005","unstructured":"Neumann, I.  et al. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol. Dial. Transplant. 20, 96\u2013104 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013225_CR18","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K de Groot","year":"2005","unstructured":"de Groot, K.  et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461\u20132469 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR19","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/art.34547","volume":"64","author":"M Faurschou","year":"2012","unstructured":"Faurschou, M.  et al. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3472\u20133477 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/art.37794","volume":"65","author":"M Faurschou","year":"2013","unstructured":"Faurschou, M.  et al. Reply. Arthritis Rheum. 65, 844 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/art.37791","volume":"65","author":"CA Langford","year":"2013","unstructured":"Langford, C. A. & Hoffman, G. S. Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou  et al. Arthritis Rheum. 65, 843 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.lpm.2013.02.067","volume":"42","author":"RB Jones","year":"2013","unstructured":"Jones, R. B. A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: \u201cMYCYC\u201d. On behalf of the European vasculitis study group [abstract]. Presse Med. 42, 678\u2013679 (2013).","journal-title":"Presse Med."},{"key":"BFnrneph2013225_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/BOR.0b013e32834120c1","volume":"23","author":"A Casian","year":"2011","unstructured":"Casian, A. & Jayne, D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr. Opin. Rheumatol. 23, 12\u201317 (2011).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrneph2013225_CR24","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DR Jayne","year":"2007","unstructured":"Jayne, D. R.  et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180\u20132188 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013225_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/ki.2013.131","volume":"84","author":"M Walsh","year":"2013","unstructured":"Walsh, M.  et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 84, 397\u2013402 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph2013225_CR26","unstructured":"US National Library of Medicine. Clinicaltrials.gov [online], (2013)."},{"key":"BFnrneph2013225_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2215\/CJN.03680412","volume":"8","author":"RJ Pepper","year":"2013","unstructured":"Pepper, R. J.  et al. Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 8, 219\u2013224 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013225_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ndt\/gfq360","volume":"26","author":"WM Szpirt","year":"2011","unstructured":"Szpirt, W. M., Heaf, J. G. & Petersen, J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis\u2014a clinical randomized controlled trial. Nephrol. Dial. Transplant. 26, 206\u2013213 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013225_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","volume":"57","author":"M Walsh","year":"2011","unstructured":"Walsh, M.  et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am. J. Kidney Dis. 57, 566\u2013574 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013225_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1055\/s-0031-1279830","volume":"32","author":"A Casian","year":"2011","unstructured":"Casian, A. & Jayne, D. Management of alveolar hemorrhage in lung vasculitides. Semin. Respir. Crit. Care Med. 32, 335\u2013345 (2011).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"BFnrneph2013225_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/03009742.2012.754939","volume":"42","author":"Hruskova","year":"2013","unstructured":"Hruskova,  et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand. J. Rheumatol. 42, 211\u2013214 (2013).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrneph2013225_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones, R. B.  et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211\u2013220 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013225_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H.  et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013225_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2249.2011.04321.x","volume":"164","author":"RB Jones","year":"2011","unstructured":"Jones, R. B., Walsh, M. & Jayne, D. R. Two year follow up results from a randomised trial of RTX versus CyP for ANCA-associated vasculitis: RITUXVAS [abstract]. Clin. Exp. Immunol. 164, 57 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph2013225_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks, U.  et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417\u2013427 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013225_CR36","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/art.38044","volume":"65","author":"EM Miloslavsky","year":"2013","unstructured":"Miloslavsky, E. M.  et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 65, 2441\u20132449 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR37","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.lpm.2013.01.048","volume":"42","author":"JM Clain","year":"2013","unstructured":"Clain, J. M. & Specks, U. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States. Presse Med. 42, 530\u2013532 (2013).","journal-title":"Presse Med."},{"key":"BFnrneph2013225_CR38","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh, M., Merkel, P. A., Mahr, A. & Jayne, D. The effects of duration of glucocorticoid therapy on relapse rate in anti-neutrophil cytoplasm antibody associated vasculitis: a meta-analysis. Arthritis Care Res. 62, 1166\u20131173 (2010).","journal-title":"Arthritis Care Res."},{"key":"BFnrneph2013225_CR39","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/ndt\/gfr507","volume":"26","author":"JW Cohen Tervaert","year":"2011","unstructured":"Cohen Tervaert, J. W. Rituximab in ANCA-associated vasculitis: a revolution? Nephrol. Dial. Transplant. 26, 3077\u20133079 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013225_CR40","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","volume":"26","author":"N Mansfield","year":"2011","unstructured":"Mansfield, N.  et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol. Dial. Transplant. 26, 3280\u20133286 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013225_CR41","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/rheumatology\/ker150","volume":"51","author":"MJ Guerry","year":"2012","unstructured":"Guerry, M. J.  et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51, 634\u2013643 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2013225_CR42","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones, R. B.  et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2156\u20132168 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR43","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","volume":"34","author":"M Martinez Del Pero","year":"2009","unstructured":"Martinez Del Pero, M.  et al. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin. Otolaryngol. 34, 328\u2013335 (2009).","journal-title":"Clin. Otolaryngol."},{"key":"BFnrneph2013225_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ki.2010.558","volume":"79","author":"SM Hamour","year":"2011","unstructured":"Hamour, S. M. & Salama, A. D. ANCA comes of age-but with caveats. Kidney Int. 79, 699\u2013701 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2013225_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/ki.2010.489","volume":"79","author":"AS Bomback","year":"2011","unstructured":"Bomback, A. S.  et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 79, 757\u2013764 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2013225_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.lpm.2013.02.069","volume":"42","author":"C Pagnoux","year":"2013","unstructured":"Pagnoux, C.  et al. Treatment of systemic necrotizing vasculitides in patients &gt;65 years old: results of the multicentre randomized CORTAGE trial [abstract]. Presse Med. 42, 679\u2013680 (2013).","journal-title":"Presse Med."},{"key":"BFnrneph2013225_CR47","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1136\/ard.2010.130203","volume":"69","author":"JU Holle","year":"2010","unstructured":"Holle, J. U.  et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann. Rheum. Dis. 69, 1934\u20131939 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR48","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3899\/jrheum.100518","volume":"38","author":"C Pagnoux","year":"2011","unstructured":"Pagnoux, C.  et al. Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. J. Rheumatol. 38, 475\u2013478 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrneph2013225_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0025-6196(12)65279-3","volume":"60","author":"RA DeRemee","year":"1985","unstructured":"DeRemee, R. A., McDonald, T. J. & Weiland, L. H. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin. Proc. 60, 27\u201332 (1985).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrneph2013225_CR50","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/art.1780310821","volume":"31","author":"RA DeRemee","year":"1988","unstructured":"DeRemee, R. A. The treatment of Wegener's granulomatosis with trimethoprim\/sulfamethoxazole: illusion or vision? Arthritis Rheum. 31, 1068\u20131074 (1988).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/oxfordjournals.qjmed.a030133","volume":"89","author":"E Reinhold-Keller","year":"1996","unstructured":"Reinhold-Keller, E.  et al. Response to trimethroprim-sulfamethoxazole (T\/S) in Wegener's granulomatosis (WG) depends on the phase of disease. QJM 89, 15\u201323 (1996).","journal-title":"QJM"},{"key":"BFnrneph2013225_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.autrev.2008.07.020","volume":"8","author":"CG Kallenberg","year":"2008","unstructured":"Kallenberg, C. G. & Tadema, H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to \u201cautoimmunity and infection\u201d. Autoimmun. Rev. 8, 29\u201332 (2008).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneph2013225_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich, B.  et al. EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66, 605\u2013617 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/BOR.0b013e3283529756","volume":"24","author":"A Rutgers","year":"2012","unstructured":"Rutgers, A. & Kallenberg, C. G. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr. Opin. Rheumatol. 24, 245\u2013251 (2012).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrneph2013225_CR55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle, J. U.  et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann. Rheum. Dis. 71, 327\u2013333 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR56","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"DR Jayne","year":"2000","unstructured":"Jayne, D. R.  et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93, 433\u2013439 (2000).","journal-title":"QJM"},{"key":"BFnrneph2013225_CR57","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.23147","volume":"58","author":"V Martinez","year":"2008","unstructured":"Martinez, V.  et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 58, 308\u2013317 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR58","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2007.071936","volume":"67","author":"C Mukhtyar","year":"2008","unstructured":"Mukhtyar, C.  et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 67, 1004\u20131010 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR59","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth, A. D.  et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41, 776\u2013784 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013225_CR60","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh, M.  et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 542\u2013548 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR61","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C.  et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310\u2013317 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013225_CR62","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/rheumatology\/kem146a","volume":"46","author":"C Lapraik","year":"2007","unstructured":"Lapraik, C.  et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46, 1615\u20131616 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2013225_CR63","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne, D.  et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36\u201344 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013225_CR64","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux, C.  et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790\u20132803 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013225_CR65","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra, T. F.  et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304, 2381\u20132388 (2010).","journal-title":"JAMA"},{"key":"BFnrneph2013225_CR66","doi-asserted-by":"crossref","unstructured":"WGET Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351\u2013361 (2005).","DOI":"10.1056\/NEJMoa041884"},{"key":"BFnrneph2013225_CR67","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","volume":"46","author":"C Metzler","year":"2007","unstructured":"Metzler, C.  et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46, 1087\u20131091 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2013225_CR68","unstructured":"European Vasculitis Study Group. Clinical Trial Protocol: REMAIN. [online], (2006)."},{"key":"BFnrneph2013225_CR69","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2005060616","volume":"17","author":"MA Little","year":"2006","unstructured":"Little, M. A.  et al. Therapeutic effect of anti-TNF-\u03b1 antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 17, 160\u2013169 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013225_CR70","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba, R.  et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 64, 3770\u20133778 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR71","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2215\/CJN.08821209","volume":"5","author":"EP Rhee","year":"2010","unstructured":"Rhee, E. P., Laliberte, K. A. & Niles, J. L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin. J. Am. Soc. Nephrol. 5, 1394\u20131400 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013225_CR72","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith, R. M.  et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3760\u20133769 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR73","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"RF van Vollenhoven","year":"2010","unstructured":"van Vollenhoven, R. F.  et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 37, 558\u2013567 (2010).","journal-title":"J. Rheumatol."},{"key":"BFnrneph2013225_CR74","doi-asserted-by":"crossref","unstructured":"van Vollenhoven, R. F.  et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. (2012).","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"BFnrneph2013225_CR75","unstructured":"US National Library of Medicine. Clinicaltrials.gov [online], (2013)."},{"key":"BFnrneph2013225_CR76","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.lpm.2013.01.050","volume":"42","author":"P Charles","year":"2013","unstructured":"Charles, P. & Guillevin, L. S3. Rituximab for ANCA-associated vasculitides: the French experience. Presse Med. 42, 534\u2013536 (2013).","journal-title":"Presse Med."},{"key":"BFnrneph2013225_CR77","unstructured":"US National Library of Medicine. Clinicaltrials.gov [online], (2013)."},{"key":"BFnrneph2013225_CR78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman, C. A., Cohen Tervaert, J. W., De Jong, P. E. & Kallenberg, C. G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N. Engl. J. Med. 335, 16\u201320 (1996).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 4","key":"BFnrneph2013225_CR79","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","volume":"14","author":"K Zycinska","year":"2009","unstructured":"Zycinska, K., Wardyn, K. A., Zielonka, T. M., Krupa, R. & Lukas, W. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur. J. Med. Res. 14 (Suppl. 4), 265\u2013267 (2009).","journal-title":"Eur. J. Med. Res."},{"key":"BFnrneph2013225_CR80","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1002\/art.23800","volume":"58","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux, C.  et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908\u20132918 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR81","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/rheumatology\/keq244","volume":"49","author":"C Pierrot-Deseilligny Despujol","year":"2010","unstructured":"Pierrot-Deseilligny Despujol, C., Pouchot, J., Pagnoux, C., Coste, J. & Guillevin, L. Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49, 2181\u20132190 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2013225_CR82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","volume":"120","author":"AC Stegeman","year":"1994","unstructured":"Stegeman, A. C.  et al. Association of chronic nasal carriage of staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann. Intern. Med. 120, 12\u201317 (1994).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2013225_CR83","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","volume":"43","author":"MM Boomsma","year":"2000","unstructured":"Boomsma, M. M.  et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43, 2025\u20132033 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013225_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2005.09.022","volume":"47","author":"R Birck","year":"2006","unstructured":"Birck, R., Schmitt, W. H., Kaelsch, I. A. & van der Woude, F. J. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am. J. Kidney Dis. 47, 15\u201323 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013225_CR85","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","volume":"147","author":"JD Finkielman","year":"2007","unstructured":"Finkielman, J. D.  et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 147, 611\u2013619 (2007).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2013225_CR86","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","volume":"51","author":"G Tomasson","year":"2012","unstructured":"Tomasson, G., Grayson, P. C., Mahr, A. D., Lavalley, M. & Merkel, P. A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis. Rheumatology (Oxford) 51, 100\u2013109 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2013225_CR87","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou, M.  et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100\u2013105 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrneph2013225_CR88","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","volume":"41","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht, P.,  et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41, 1303\u20131307 (2002).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2013225_CR89","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/ndt\/gfi117","volume":"20","author":"MS Joy","year":"2005","unstructured":"Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J. & Nachman, P. H. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant. 20, 2725\u20132732 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013225_CR90","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/01.ASN.0000048716.42876.14","volume":"14","author":"R Birck","year":"2003","unstructured":"Birck, R.  et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. 14, 440\u2013447 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013225_CR91","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1523-1755.2004.00534.x","volume":"65","author":"WH Schmitt","year":"2004","unstructured":"Schmitt, W. H.,  et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440\u20131448 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph2013225_CR92","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","volume":"43","author":"C Metzler","year":"2004","unstructured":"Metzler, C., Fink, C., Lamprecht, P., Gross, W. L. & Reinhold-Keller, E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43, 315\u2013320 (2004).","journal-title":"Rheumatology (Oxford)"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.225","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:33:42Z","timestamp":1650051222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,5]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["BFnrneph2013225"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2013.225","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,5]]},"assertion":[{"value":"5 November 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W. L. Gross declares that he has received honoraria for speaking and advisory board fees from Hoffmann-La Roche and GlaxoSmithKline. K. de Groot declares that she has received honoraria for speaking from Hoffmann\u2013La Roche. U. Sch\u00f6nermarck declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}